FDA cracking down on use of petitions to delay generics

FDA cracking down on use of petitions to delay generics

Source: 
BioCentury
snippet: 

FDA released draft guidance Tuesday aimed at reducing the use of 505(q) Citizen's Petitions intended to delay market entry of generic drugs. In a statement, FDA Commissioner Scott Gottlieb said some parties have used the petitions among "anticompetitive techniques."